Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
BROAD ARROW WELCOMES RENOWNED CAR SPECIALISTS TO EUROPEAN TEAM
09:01am, Thursday, 30'th Jan 2025
PHILIP KANTOR, GREGORY TUYTENS, AND PAUL GAUCHER JOIN BROAD ARROW AND BRING A COMBINED 50 YEARS OF EXPERIENCE IN THE COLLECTOR CAR AUCTION INDUSTRY | VALÉRIE SIMONET, RYAN CIGANA, AND SIMON DRAKE TO
Billionaire Investor Sold These 5 Stocks And Loading Up On These Companies Instead
09:42am, Wednesday, 29'th Jan 2025
According to LCH Investments, over 200 hedge funds are Tiger Cubs, funds started by former employees of Tiger Management, the iconic hedge fund founded by Julian Robertson in 1980.
BROAD ARROW OFFERS 1954 JAGUAR D-TYPE 'OKV 2' WORKS COMPETITION CAR WITHOUT RESERVE AT 2025 AMELIA AUCTION
11:01am, Monday, 27'th Jan 2025
AMONG THE MOST IMPORTANT SPORTS RACING CARS OF ALL TIME | D-TYPE OFFERED WITHOUT RESERVE, ESTIMATED TO BRING $6.5-8.5M AT MARCH 7-8 AUCTION AMONG THE MOST IMPORTANT SPORTS RACING CARS OF ALL TIME | D-
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
08:50am, Monday, 20'th Jan 2025
SHANGHAI , Jan. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
08:50am, Monday, 13'th Jan 2025
SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
09:00am, Thursday, 09'th Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patien
Credit Agricole Nord de France - Avis de mise à disposition du bilan de contrat de liquidité
08:04am, Friday, 03'rd Jan 2025
Lille, le 3 janvier 2025 Avis de mise à disposition du bilan semestriel 2024 du contrat de liquidité du Crédit Agricole Nord de France La Caisse régionale du Crédit Agricole Nord de France ann
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
08:50am, Tuesday, 31'st Dec 2024
SHANGHAI , Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
08:50am, Monday, 30'th Dec 2024
SHANGHAI , Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies
Crown88 Renews Partnership with Taiwanese Influencer Avis for Year 2025
01:46pm, Sunday, 29'th Dec 2024
Singapore, Singapore--(Newsfile Corp. - December 29, 2024) - Crown88 , Singapore's largest online gaming platform since 2010, is pleased to announce the renewal of its successful partnership with Taiw
Why You Should Hold Avis Budget Stock in Your Portfolio Now
01:25pm, Friday, 27'th Dec 2024
CAR benefits from strong demand, fleet management and technology investments, which boost profitability. However, lack of dividends and low liquidity pose risks.
Marker Therapeutics Announces $16.1 Million Private Placement
08:06am, Thursday, 19'th Dec 2024
Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Strategic financing supports clinical
Hemogenyx Pharmaceuticals partners with Kure.ai for ultrafast CAR-T manufacturing
02:27am, Thursday, 19'th Dec 2024
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF). the UK-listed biopharmaceutical company focused on treatments for blood cancers, has entered a collaboration with Kure.ai to develop an ultrafast m
75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of Dece
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleu
